Acarbose is an oral medication used to treat type 2 (noninsulin-dependent) diabetes.

The antihyperglycemic action of Acarbose results from a competitive, reversible inhibition of pancreatic alpha-amylase and membrane-bound intestinal alpha-glucoside hydrolase enzymes. Available for Android and iOS devices.We comply with the HONcode standard for trustworthy health information - No increased incidence of renal tumors was found in either of these Wistar rat studies. It is used when high blood sugar levels cannot be controlled by diet and exercise alone. The maximum recommended dose for patients >60 kg is 100 mg t.i.d.Sulfonylurea agents or insulin may cause hypoglycemia. In cases of overdosage the patient should not be given drinks or meals containing carbohydrates (polysaccharides, oligosaccharides and disaccharides) for the next 4 to 6 hours.There is no fixed dosage regimen for the management of diabetes mellitus with Acarbose tablets or any other pharmacologic agent. Entocort EC is a steroid that reduces inflammation in the body. The inactive ingredients are corn starch, microcrystalline cellulose, magnesium stearate, croscarmellose sodium, and colloidal anhydrous silica.Acarbose is a complex oligosaccharide that delays the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals. If the prescribed diet is not observed, the intestinal side effects may be intensified. Systemic non-enzymatic protein glycosylation, as reflected by levels of glycosylated hemoglobin, is a function of average blood glucose concentration over time.In contrast to sulfonylureas, Acarbose does not enhance insulin secretion.

Although there were no statistically significant differences among the mean results for doses ranging from 50 to 300 mg t.i.d., some patients may derive benefit by increasing the dosage from 50 to 100 mg t.i.d. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. Limited published studies report in pregnant women; however, data insufficient to inform a drug-associated risk for major birth defects and miscarriage; there are clinical considerations; in animal reproduction studies with pregnant rats and rabbits, administration of subcutaneous budesonide during organogenesis at doses approximately 0.5 times or 0.05 … Long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine >2.0 mg/dL) have not been conducted. In the Acarbose-treated patients on insulin, there was a statistically significant reduction in HbA1c at six months, and a trend for a reduction at one year.Acarbose tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Acarbose is contraindicated in patients with known hypersensitivity to the drug. The therapeutic goal should be to decrease both postprandial plasma glucose and glycosylated hemoglobin levels to normal or near normal by using the lowest effective dose of Acarbose tablets, either as monotherapy or in combination with sulfonylureas, insulin or metformin.The recommended starting dosage of Acarbose tablets is 25 mg given orally three times daily at the start (with the first bite) of each main meal. Acarbose slows the digestion of carbohydrates in the body, which helps control blood sugar levels. This study was repeated with a similar outcome. Forty-one of these 62 patients received treatment with 100 mg t.i.d.

It is recommended that serum transaminase levels be checked every 3 months during the first year of treatment with Acarbose and periodically thereafter.